PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE LANDSCAPE PART 07: MARKET SEGMENTATION BY APPLICATION Market segmentation by application Comparison by application Oral - Market size and forecast 2018-2023 Topical - Market size and forecast 2018-2023 Other RoA - Market size and forecast 2018-2023 Market opportunity by application PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS Application of novel technologies for PDE inhibitors development Growing geriatric population Rising burden of chronic diseases PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Bayer AG Eli Lilly and Co. GlaxoSmithKline Plc Pfizer Inc. Vivus Inc. PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO   Exhibit 1: Global pharmaceuticals market Exhibit 2: Segments of global pharmaceuticals market Exhibit 3: Market characteristics Exhibit 4: Market segments Exhibit 5: Some of the commercially available PDE inhibitors Exhibit 6: Disease targets for different PDE inhibitors Exhibit 7: Market definition - Inclusions and exclusions checklist Exhibit 8: Market size 2018 Exhibit 9: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Some of the phase III clinical trials of PDE inhibitors Exhibit 20: Application - Market share 2018-2023 (%) Exhibit 21: Comparison by application Exhibit 22: Oral - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Advantages of tablet dosage form Exhibit 24: Oral - Year-over-year growth 2019-2023 (%) Exhibit 25: Topical - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Topical - Year-over-year growth 2019-2023 (%) Exhibit 27: Other RoA - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Other RoA - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by application Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Top 3 countries in North America Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 37: Europe - Year-over-year growth 2019-2023 (%) Exhibit 38: Top 3 countries in Europe Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 40: Asia - Year-over-year growth 2019-2023 (%) Exhibit 41: Top 3 countries in Asia Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 43: ROW - Year-over-year growth 2019-2023 (%) Exhibit 44: Top 3 countries in ROW Exhibit 45: Key leading countries Exhibit 46: Market opportunity Exhibit 47: Role of PDE5 inhibitors in ED Exhibit 48: Sales of PDE5 inhibitors after the launch of generics ($ millions) Exhibit 49: Impact of drivers and challenges Exhibit 50: CDC statistics about chronic diseases in geriatric population in the US over the past few years Exhibit 51: Geriatric population scenario in the US Exhibit 52: Vendor landscape Exhibit 53: Landscape disruption Exhibit 54: Vendors covered Exhibit 55: Vendor classification Exhibit 56: Market positioning of vendors Exhibit 57: Bayer AG - Vendor overview Exhibit 58: Bayer AG - Product segments Exhibit 59: Bayer AG - Organizational developments Exhibit 60: Bayer AG - Geographic focus Exhibit 61: Bayer AG - Segment focus Exhibit 62: Bayer AG - Key offerings Exhibit 63: Bayer AG - Key customers Exhibit 64: Eli Lilly and Co. - Vendor overview Exhibit 65: Eli Lilly and Co. - Business segments Exhibit 66: Eli Lilly and Co. - Organizational developments Exhibit 67: Eli Lilly and Co. - Geographic focus Exhibit 68: Eli Lilly and Co. - Segment focus Exhibit 69: Eli Lilly and Co. - Key offerings Exhibit 70: Eli Lilly and Co. - Key customers Exhibit 71: GlaxoSmithKline Plc - Vendor overview Exhibit 72: GlaxoSmithKline Plc - Business segments Exhibit 73: GlaxoSmithKline Plc - Organizational developments Exhibit 74: GlaxoSmithKline Plc - Geographic focus Exhibit 75: GlaxoSmithKline Plc - Segment focus Exhibit 76: GlaxoSmithKline Plc - Key offerings Exhibit 77: GlaxoSmithKline Plc - Key customers Exhibit 78: Pfizer Inc. - Vendor overview Exhibit 79: Pfizer Inc. - Business segments Exhibit 80: Pfizer Inc. - Organizational developments Exhibit 81: Pfizer Inc. - Geographic focus Exhibit 82: Pfizer Inc. - Segment focus Exhibit 83: Pfizer Inc. - Key offerings Exhibit 84: Pfizer Inc. - Key customers Exhibit 85: Vivus Inc. - Vendor overview Exhibit 86: Vivus Inc. - Business segments Exhibit 87: Vivus Inc. - Organizational developments Exhibit 88: Vivus Inc. - Geographic focus Exhibit 89: Vivus Inc. - Key offerings Exhibit 90: Vivus Inc. - Key customers Exhibit 91: Validation techniques employed for market sizing Exhibit 92: Definition of market positioning of vendors

Bayer AG, Eli Lilly and Co., GlaxoSmithKline Plc, Pfizer Inc., and Vivus Inc.